Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Japanese encephalitis vaccine - sanofi pasteur

Drug Profile

Japanese encephalitis vaccine - sanofi pasteur

Alternative Names: ChimeriVax-JE; Imojev; JE-CV; Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®); Single-dose Japanese encephalitis vaccine - sanofi pasteur

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acambis
  • Developer Sanofi Pasteur
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Japanese encephalitis

Most Recent Events

  • 12 Oct 2016 Launched for Japanese encephalitis (Prevention) in South Korea (SC) prior to October 2016
  • 30 Jun 2016 Sanofi pasteur completes a phase III clinical trial in Japanese encephalitis (Prevention, In infants, In children, In adolescents, In adults) in Vietnam (SC) (NCT02492165)
  • 01 Nov 2013 Sanofi pasteur initiates enrolment in a phase IV post-approval trial in Japanese encephalitis (prevention, in children aged 1-4 years) in Thailand (NCT01981967)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top